Tirzepatide: The Potential Game Changer for Obesity and Weight Loss

Eli Lilly's weight loss drug tirzepatide resulted in an average weight loss of up to 34 pounds or 16% of body weight in a clinical trial of overweight patients with Type 2 diabetes. The company plans to apply for FDA approval for the drug in the coming weeks, which could open up the opportunity for many more people to benefit from tirzepatide. The drug mimics two naturally produced hormones in the gut that signal to the brain when a person is full, suppressing their appetite. However, some experts have criticized the increased use of the drugs as a potentially damaging extension of diet culture.